Refractec's ViewPoint
This article was originally published in The Gray Sheet
Executive Summary
Phase III clinical trial of the "laserless" conductive keratoplasty device for presbyopia gains FDA go-ahead. System uses radio frequency energy to shrink collagen tissue within the cornea, thus reshaping it and eliminating the need for reading glasses, firm explains. FDA also has accepted a final module of the Irvine, California firm's PMA for hyperopia treatment
You may also be interested in...
Refractec's ViewPoint System May Provide Alternative To LASIK Surgery
FDA's Ophthalmic Devices Panel review of Refractec's ViewPoint conductive keratoplasty system to treat spherical hyperopia in patients over 40 has been rescheduled for Nov. 30.
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.